Dual Reinforcement Contingency Management for Alcohol Use Disorders

Alcohol Use Disorder Clinical Trial

— Peth  

Official title:

Dual Reinforcement Contingency Management for Alcohol Use Disorders

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04064463
• Other study ID #: 19-146-2
• Status: Recruiting
• Phase: N/A
• Start date: January 22, 2020
• Est. completion date: May 2025

Study information

• Verified date: April 2024
• Source: UConn Health
• Contact: Ruth Fetter
• Phone: 860-679-4556
• Email: fetter[@]uchc.edu
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Phosphatidylethanol (PEth) is a direct biomarker of alcohol that can detect moderate to heavy drinking with high sensitivity and specificity over 3-week periods. Reinforcing negative PEth results alongside attendance may increase the proportion of participants who respond to CM during and post treatment. In the proposed study, the investigators will collect PEth samples every 3 weeks for 12 weeks in 150 participants initiating outpatient treatment for alcohol use disorders. Using a two-group randomized design, participants will be assigned to standard care with PEth monitoring alone or with CM for attending treatment and submitting PEth negative samples. Compared to standard care and monitoring, the investigators expect that the CM intervention will result in greater attendance, more PEth negative samples, and higher proportions of self-reported non-drinking days, along with lower proportions of heavy drinking days, over the short term and the long term, measured throughout a 12-month follow-up. The investigators anticipate that the reinforcement intervention may decrease other drug use and sexual risk behaviors that spread HIV, reduce psychiatric symptoms, and improve quality of life as well.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 150
• Est. completion date: May 2025
• Est. primary completion date: May 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• in intensive outpatient treatment

• DSM-5 diagnosis of an alcohol use disorder

Exclusion Criteria:

• have a condition that may hinder study participation

Related Conditions & MeSH terms

• Alcohol Drinking
• Alcohol Use Disorder
• Alcoholism
• Contingency Management

Intervention

Behavioral:
• Standard care
standard treatment for substance use disorders, along with sample monitoring
• Contingency management
Participants can earn reinforcement for attending group and abstinence from alcohol

Locations

Country	Name	City	State
United States	The Village	Hartford	Connecticut

Sponsors (2)

Lead Sponsor	Collaborator
UConn Health	National Institute on Alcohol Abuse and Alcoholism (NIAAA)

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Group attendance	longest consecutive days attended groups	12 weeks
Primary	Alcohol abstinence	number of negative PEth samples	12 weeks